ZyVersa Therapeutics Prices $5M Public Offering
Portfolio Pulse from Benzinga Newsdesk
ZyVersa Therapeutics has priced a public offering aiming to raise $5 million through the sale of 4 million shares and accompanying warrants. The offering includes Series A and Series B warrants, exercisable at $1.25 per share, with Series A expiring in five years and Series B in eighteen months.
December 07, 2023 | 7:58 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ZyVersa Therapeutics is raising $5 million through a public offering of shares and warrants, which may dilute current shareholders but provide capital for operations and growth.
Public offerings often lead to dilution of existing shares, which can negatively impact the stock price in the short term. However, the capital raised is intended for growth, which could have positive long-term effects.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100